Department of Haematology, University Hospitals Plymouth NHS Trust, Plymouth, UK.
Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Br J Haematol. 2020 May;189(4):684-688. doi: 10.1111/bjh.16416. Epub 2020 Feb 3.
Patients with mantle cell lymphoma progressing on Bruton's tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients progressing on BTKi received R-BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete response 60%) and 31% were bridged to allogeneic stem cell transplant (alloSCT). Median progression-free survival was 10.1 months (95% confidence interval (CI) 6·9-13·3) and median overall survival was 12·5 months (95% CI 11·0-14·0). In those consolidated with alloSCT only one patient relapsed. R-BAC demonstrates a high response rate in the post-BTKi setting and in transplant eligible patients is an effective bridge to alloSCT.
在 Bruton 酪氨酸激酶抑制剂 (BTKi) 治疗后进展的套细胞淋巴瘤患者预后极差，目前尚无标准治疗方法。在这项回顾性队列研究中，接受 BTKi 治疗后进展的患者接受了 R-BAC（利妥昔单抗、苯达莫司汀、阿糖胞苷）治疗。总体缓解率为 83%（完全缓解率为 60%），31%的患者桥接接受异基因造血干细胞移植 (alloSCT)。无进展生存期的中位数为 10.1 个月（95%置信区间 [CI]：6.9-13.3），总生存期的中位数为 12.5 个月（95%CI：11.0-14.0）。在仅接受 alloSCT 巩固治疗的患者中，只有 1 例复发。R-BAC 在 BTKi 治疗后显示出较高的缓解率，在适合移植的患者中是异基因造血干细胞移植的有效桥接。
